Anhedonia in the age of RDoC

Bedwell, Jeffrey S.; Gooding, Diane C.; Chan, Chi Chuen; Trachik, Benjamin

doi:10.1016/j.schres.2014.10.028

Cited by 41 publications

(31 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies explored topics related to established domains, but focused on constructs not explicitly defined as a construct in the RDoC matrix, such as neuroticism (i.e., the tendency to experience negative affect; Bedwell et al, 2014) and anhedonia (i.e., the inability to feel pleasure; Webb et al, 2016). One of these studies, Østergaard et al (2014), overtly proposed that melancholia should be included as an additional construct within the Negative Valence Systems domain.…”

Section: Resultsmentioning

confidence: 99%

Six Years of Research on the National Institute of Mental Health’s Research Domain Criteria (RDoC) Initiative: A Systematic Review

Carcone

Ruocco

2017

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Six years have passed since the National Institute of Mental Health (NIMH) in the United States launched the Research Domain Criteria (RDoC) initiative. The RDoC introduces a framework for research on the biology of mental illness that integrates research findings across multiple levels of information. The framework outlines constructs that represent specific quantifiable dimensions of behavior (e.g., responses to acute threat, cognitive control) and corresponding units of analysis that can be used to study the constructs, beginning at the levels of genes, molecules, cells, circuits and physiology, and moving up to behaviors and self-reports. In this systematic review, a literature search was conducted to synthesize empirical research published since the proposal of the framework that incorporated the RDoC. Forty-eight peer-reviewed scholarly articles met eligibility criteria for the review. Studies differed according to whether they analyzed RDoC constructs and units of analysis within vs. between clinically-diagnosed and non-psychiatric samples. The most commonly studied constructs were subsumed within the domains of Negative Valence Systems, Positive Valence Systems and Cognitive Systems, providing initial results which primarily connected genetics, brain circuits and physiology research findings with behavior and self-reports. Prospects for future research adopting the RDoC matrix and utilizing a dimensional approach to studying the biology of mental illness are discussed.

show abstract

Section: Resultsmentioning

confidence: 99%

Six Years of Research on the National Institute of Mental Health’s Research Domain Criteria (RDoC) Initiative: A Systematic Review

Carcone

Ruocco

2017

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…This attempt aims at studying behavioral dimensions independently from the clinical classification systems whose validity is questioned. Investigating pharmacological strategies to improve anhedonia rather than depression may, therefore, be more accurate and might also prove beneficial for clinical states of prominent anhedonia without depression, such as borderline personality disorder and schizophrenia [26]. Patients with this prevalent lifelong disorder experience disabling emptiness and anhedonia unrelated necessarily to depression, and there are currently no available pharmacotherapies to target them.…”

Section: Discussionmentioning

confidence: 99%

Prohedonic Effect of Cannabidiol in a Rat Model of Depression

Shoval

Shbiro²,

Hershkovitz³

et al. 2016

Neuropsychobiology

View full text Add to dashboard Cite

Background: Accumulating evidence suggests that cannabidiol (CBD) may be an effective and safe anxiolytic agent and potentially also an antidepressant. Aim: The objective of this study was to further examine these properties of CBD using the ‘depressive-like' Wistar-Kyoto (WKY) rat, focusing on the drug's effect on anhedonia-like behaviors. Methods: Forty-eight WKY and 48 control Wistar adult male rats were pretreated orally with CBD (15, 30 and 45 mg/kg) or vehicle. The saccharin preference test (SPT), the elevated plus maze (EPM) test and the novel object exploration (NOE) test were used. Results: CBD showed a prohedonic effect on the WKY rats at 30 mg/kg in the SPT. In the NOE, CBD increased exploration of the novel object and locomotion at 45 mg/kg and increased locomotion at 15 mg/kg, indicating an improvement in the characteristically low motivation of WKY rats to explore. There was no similar effect at any dose in the EPM or in open-field behavior in the habituation to the NOE. Conclusions: These findings extend the limited knowledge on the antidepressant effect of CBD, now shown for the first time in a genetic animal model of depression. These results suggest that CBD may be beneficial for the treatment of clinical depression and other states with prominent anhedonia.

show abstract

“…Bedwell et al (2014) argued that anhedonia is a dimensional transdiagnostic symptom. Their findings showed that anhedonia was present across different diagnoses and did not differ depending on a history of psychosis, which is consistent with the growing number of reports of increased levels of subjective experiential anhedonia such as the TEPS in individuals with schizophrenia and other related disorders with anhedonia.…”

Section: Introductionmentioning

confidence: 99%